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Background. Vernal keratoconjunctivitis (VKC) is a rare ocular surface inflammatory disease that affects mainly boys in the first
decade of life. Clinical observations show that it generally regresses spontaneously with the onset of puberty, but therapeutic
measures must be taken before then to control the course of the disease. Purpose.To evaluate the role of the lacrimal mucous
component in VKC patients and compare tear ferning test (TFT) modifications, MUC5AC levels in tears, and density of
conjunctival goblet cells to clinical characteristics before and after treatment with cyclosporine A (CY) in eye drops. Methods.
Forty-seven patients affected by VKC and 30 healthy subjects aged between 3 and 16 years of life were enrolled. All individuals
were submitted to complete eye examination and skin prick test (SPT) for the most common allergens. 'en, they were subjected
to collection of the tears and to impression cytology to evaluate TFT, MUC5AC levels, and conjunctival goblet cell density, before
and after treatment with CY in eye drops. Results. Comparing the VKC group vs. the control group at baseline, a significant
alteration in the degree of the ferns was found, indicating a pathological condition of the lacrimal mucous layer. In addition, an
increased number of goblet cells were observed in the patients. 'e concentration of lacrimal secretory mucins (MUC5AC) did
not show significant differences between the 2 groups. Patients treated with CY have reported improvements of some signs and
symptoms of disease activity, including TFT, and a tendency of conjunctival goblet cell density to normalise. Conclusions. 'e
results obtained demonstrated for the first time a significant alteration of the lacrimal mucin component evaluated in the VKC
group, and an improvement of the latter after CY therapy.
1. Introduction
Vernal keratoconjunctivitis (VKC) is an ocular chronic
inflammation that mainly affects children (males/females �
3/1) in the first decade of life and tends to regress generally
in puberty [1, 2]. 'is form is relatively rare and is more
frequent in warm, dry, and windy climates, such as the
Mediterranean, Central Africa, India, and South America.
Type I hypersensitivity linked to immunoglobulin E (IgE)
and mediated '2 lymphocytes appears to be, in fact,
only one of the cofactors of the disease in which environ-
mental, hormonal, hereditary, and immune-allergological
factors interact; so, the etiopathogenesis of this disease is
multifactorial [2, 3]. 'e typical ocular symptoms are
conjunctival hyperemia, itching, tearing, photophobia, and
foreign body sensation. 'e recent literature distinguishes
this disease into 4 types [3–5]:
(1) Tarsal form: small, medium, and/or giant papillae on
the tarsal conjunctiva are visible with the eversion of
the upper eyelid
(2) Limbal form: nodules or Horner–Trantas dots are
present on the corneal limbus
(3) Corneal form: alterations of the corneal stroma and
nerves are associated with intense hypersensitivity
and photophobia
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(4) Mixed form which has intermediate characteristics
of the 3 types
'ough called “vernal”, VKC often has a chronic course
throughout the year with seasonal outbreaks, in spring and
summer, characterised by a worsening of symptoms, and
frequent corneal involvement, ranging from superficial
punctate keratitis with corneal ulcers that compromise visual
function [3–5]. Diagnosis is based on clinical features, age,
familiarity, disease progression, and the presence of typical
clinical signs and symptoms. Allergic mediators such as his-
tamine, leukotrienes, and prostaglandins directly stimulate
secretory activity of conjunctival goblet cells, while in-
flammatory cytokines may regulate the secretion, proliferation,
and apoptosis of the many cells involved. In fact, alterations in
the expression of mucins on the ocular surface are associated
with numerous pathologies, and it has been observed that
a reduction or a dysfunction of the conjunctival caliciform cells
results in instability of the tear film [6, 7].
In particular, several transmembrane mucins (MUC1,
MUC4, and MUC16), and secretion mucins have been
identified (MUC2 andMUC5AC) on the ocular surface [6–8].
MUC5AC is the major secretory mucin of the tear film, and its
concentration in human tears ranges from 1 to more than
200ng/mL. Moreover, the production of MUC5AC by the
goblet cells is a target of regulation for allergic and in-
flammatory mediators produced by innate and adaptive im-
munity cells. Secretory mucous membranes remove allergens
and pathogens from the ocular surface and play an important
lubricating activity in epithelial cells. In fact, in patients with
VKC, there is an increase in the number of conjunctival goblet
cells; following the use of antihistamines and anti-
inflammatory topical drugs with VKC, there is a reduction
in the number of conjunctival caliciform cells to normal values
[9–11]. Moreover, the expression ofMUC5ACmRNA derived
from goblet cells is reduced in eyes with corneal shield ulcers.
At the same time, MUC1, MUC2, and MUC4 expression
increases as a possible defense mechanism to compensate for
the reduced protective effect of MUC5AC [8–10].
Cyclosporine A (CY) is a neutral, hydrophobic, cyclic
polypeptide calcineurin inhibitor which was first purified in
1979 from cultures of the fungus Tolypocladium inflatum
gams and from other imperfect fungi. Topical CY does not
penetrate ocular tissues due to its poor water solubility and
acts on conjunctiva as an immunomodulator, causing a re-
duction of inflammatory cells, particularly Tcells, HLA-DR+
cells, and plasma cells [5–7, 12].
'e purpose of this study was to evaluate the role of the
lacrimal mucous component in VKC patients. In particular,
the mucous component of the tear film was evaluated by tear
ferning test (TFT), dosing of MUC5AC levels, and density of
conjunctival goblet cells. In addition, modifications of TFT,
MUC5AC levels in tears and conjunctival goblet cell density
were compared to clinical features and evaluated prior and
after treatment with topical CY.
2. Materials and Methods
We enrolled 47 children (38 males and 9 females) between 3
and 16 years of age with clinical diagnosis of VKC.'ey were
submitted to ophthalmology clinic study by the Department
of Allergology and Pediatric Immunology of the “Sapienza
University of Rome”. Also, we enrolled 30 healthy controls
(20 males and 10 females) aged 5–16 years. Inclusion criteria
for the children in the study were as follows:
(i) Diagnosis of VKC based on the child’s history and
the presence of some signs and symptoms, including
itching, photophobia, and tearing in the
spring/summer
(ii) Age between 3 and 16 years
(iii) Symptoms associated with the presence of tarsal
conjunctival papillae and/or limbal nodules, and
mucous secretion
(iv) Persistent or recurrent symptoms of VKC with little
or no response to common pharmacological
products for allergies
(v) No use of contact lenses
Exclusion criteria were as follows:
(i) Diagnosis of ocular pathologies such as glaucoma,
blepharitis, ocular infections, cheratoconus, iritis,
cataract, and other corneal or conjunctivitis
pathologies
(ii) Diagnosis of systemic pathologies such as cancer,
arteriosa hypertension, diabetes, cardiophathies,
etc.
(iii) Ocular surgery in the six months prior to inclusion
in the study
(iv) Systemic or local therapy for other pathologies
In accordance with the Helsinki Declaration, all parents
were informed about the use of their data, and informed
consent was obtained. 'e study also fully complied with
the Good Clinical Practice guidelines and was approved by
the Ethics Committee of our Hospital, Sapienza University
of Rome (Authorization Rif. CE: 2336/26.01.2012-
23/11/2015).
For each patient, the following anamnestic data were
collected: age, sex, family history of atopy, and autoim-
mune diseases, presence of associated atopic conditions,
age of VKC onset, perennial or seasonal course, and prior
topical therapy. All patients underwent a skin prick test
(SPT) for the most common inhaled and food allergens:
dog and cat epithelium, parietary, grass and olive pollen,
dust mites, pine, birch, plane and cypress, cow’s milk
proteins, eggs, fish, wheat, and soy. Patients were also
subjected to a complete eye examination with visual acuity
measurement, front and back biomicroscopy, indirect
ophthalmoscopy, and a clinical technique to evaluate the
ocular tear film by the Schirmer I test, break-time test
(BUT), fluorescein test, etc. Some clinical signs and
symptoms of pathological activity to baseline were evalu-
ated with a score from 0 to 3. 'e total score of the
signs (TSS) was calculated as the sum of the score of
conjunctival hyperemia and chemosis, conjunctival serous
and mucosal secretion, large and small tarsal papillae,
limbal dots or nodules, and superficial wound corneal
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epithelium or corneal ulceration, obtaining a TSS from 0 to
18. 'e total score of the symptoms (TSyS) was calculated
as the sum of the score of itching, photophobia, tearing, and
foreign body sensation obtaining a TSyS from 0 to 12. 'e
tears and conjunctival cells of the patients were collected to
perform: TFT, impression cytology, and MUC5AC levels.
All investigations were carried out by the same physician.
In the past, 33 patients (70.21%) had previously been
treated with antiallergic and/or anti-inflammatory topical
therapy, but without symptom control except for short
periods. All patients were prescribed a multidose bottle of
galenic preparation containing 1% CY in 15mL of 0.1%
sodium hyaluronate to be applied 3 times/day (Vismed
Light®, Medivis Srl Catania, Italy, and 1% CY). Patientswere re-evaluated 3 months after the start of topical
therapy.
2.1. Procedure
2.1.1. Tear Ferning Test (TFT). All patients and controls were
subjected to TFT. 'e technique was performed by drawing
tears from the lower marginal lacrimal meniscus with a glass
microcapillary tube. 'e collection of the material was
performed at the beginning of the ophthalmic examination
to avoid any contamination or dilution by topical anesthetics
or colorants such as fluorescein. 'e sample thus obtained
was placed on an optical microscopy slide and left to dry by
evaporation at room temperature; slides were then evaluated
at the optical microscope to classify the response to the
sifting test [13–15]. 'us, qualitative TFT was used for as-
sessment of protein denaturation according to some authors
[13–15] (Figure 1).
Type I, continuous. Large, uniform, and thickly
branched ferns without the presence of free spaces
between the ferns for the right amount of protein.
Type II, discontinuous. Abundant felcization but with
empty spaces between branches; decreased film
stability.
Type III, reduced. Sparse ferns with empty spaces and
mucin accumulations.
Type IV, no ferns, presence of clusters of degenerate
substances. Typical signs of dry eye. Tear film altered by
stability, pH, firmness, and osmolarity.
Type I was considered normal to indicate good mucous
efficiency and hence indirectly good tear film. Types II and
III were considered as a transition form to indicate a state of
difficulty in the mucus to maintain its integrity and func-
tions. In types II and III, it is possible to find needle-like
ferns instead of arboriforms due to the presence of an
abundant protein mat rich in sugars and salts which alters
the fern structure. Precipitated glycoproteins are antibodies
such as IgM, IgG, and IgE, and in allergic subjects, IgE takes
on the appearance of a small cross. Type IV was indicated as
corresponding to a profound mucosal alteration. Qualitative
TFT was evaluated with a score of 1 to 4 and calculated as
type I to IV in both patients and controls, before and after
topical therapy.
2.1.2. Conjunctival Impression Cytology. 'e patients were
also subjected to conjunctival impression cytology, taking
four samples per patient, two specimens per eye, at the level
of the nasal and temporal conjunctiva. Impression cytology
was obtained after the administration of topical anaesthesia
with 2 drops of 4% ossibuprocain. 'e filters used for the
collection were special nitrocellulose filters (Millicell-®CMCulture Plate Insert, 0.4 μm, Ø 12mm, PICM 012 50,
Millipore). 'e operator kept the membrane on the con-
junctiva for 5 seconds using the plastic support.
'e preparations were then fixed with the Bio-Fix cy-
tological fixator (Kaltek s.r.l.), placed in its original container
and numbered for subject, eye, area, and date of exam. 'e
samples were stored in a freezer at −80°C, pending semi-
Schiff (PAS) staining.
PAS colouration was performed by applying the fol-
lowing procedure to all cytology samples:
(i) periodic acid at 0.5% for 2min; washing in distilled
water
(ii) Schiff reagent for 10min; washing in running water
trays for 5 minutes
(iii) Pure haematoxylin for 2min; washing in running
water trays for 5 minutes
'e samples were then observed under NIKON Eclipse
E600 optical microscope to perform caliciform-forming cell
counts. 'e density of the goblet cells was defined as the
average of the cells per field in 3 different random fields.
2.1.3. Dosing of MUC5AC Levels. 'e tears of the patients
were collected by inserting Microsponges (Alcon Labora-
tory, Fort Worth, Texas) into the inferior tarsal conjunctiva
of both eyes for 60 seconds. 'e sponges were removed and
put in a 1.5-mL Eppendorf vial containing the subject’s
identification number, the eye examined, and the date of
withdrawal. So prepared, the sample was centrifuged, 12000
revolutions per minute (rpm) for 5 minutes, and stored in
a freezer at −80°C. 'e immunoenzymatic test (ELISA) was
performed on the samples collected to search for MUC5AC
(Abbexa). 'e exam was a direct Sandwich test. 'e tear
sample diluted at 30 :1 was added to prefilled wells with the
anti-MUC5AC antibody and left to incubate. A second
antibody conjugated to an enzyme such as peroxidase was
used to observe the positivity of the reaction. After washing
to remove excess substances, the chromogenic substrate,
tetramethylbenzidine, was added. 'en, a colourimetric
reaction was developed to allow quantification of the reagent
indirectly bound to the enzyme by means of a suitable
spectrophotometer.
2.2. Statistical Analysis. Qualitative variables were sum-
marised by percentages and counts. 'e differences between
groups were evaluated by Fisher’s test or chi-square test.
Quantitative variables were summarised by mean and
standard deviation (SD).'e differences between the groups
were evaluated by nonparametric test by Mann–Whitney.
TFT scores, the number of conjunctival goblet cells, and
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lacrimal MUC5AC levels were compared at baseline and after
therapy in the dierent groups by the t-test for independent
samples and the Wilcoxon test for paired samples. e
correlations between clinical, demographic, and biological
parameters were performed by Spearman rho. Values of
p< 0.05 were considered statistically signicant. Statistical
analysis was conducted with the SPSS 18.0 software (Statistical
Package of Social Sciences, Chicago, IL, USA).
3. Results
e study included 47 patients (38 males, 9 females) aged 3
to 16 (mean age 8.8 ± 4.7 SD years) with VKC, and 30
healthy, nonallergic controls (20 males, 10 females), aged 5
to 16 (mean age 11.3 ± 4.2 SD years). According to the
literature, VKC prevalence was higher in males than in
females (79.85% vs 20.15%) in the population we studied.
Fifty-seven percent of patients had a family history of allergic
diseases, and 12% had a parent with autoimmune disease.
Two patients had VKC in the family (cousin/father). Forty-
six percent of the patients were positive for the allergen SPT.
irty percent of the sample tested had a positive allergic
history (25% rhinitis; 5% atopic dermatitis). e average
onset of VKC was 2.7 ± 1.3 SD years before. irty patients
(63.83%) were aected by tarsal form, 12 (25.53%) by limbal
form, 3 (6.38%) by mixed form, and 2 (4.26%) by corneal
form. e VKC patients instilled 1% CY in 0.1% sodium
hyaluronate 3 times at day. en, they were re-evaluated 3
months after the start of topical therapy. e clinical and
demographic characteristics of the sample being studied are
summarised in Table 1.
e mean ages between the dierent groups were not
statistically signicant. e test results were found to be
normal in the control group and abnormal in the VKC group.
Type I
II II
III III
IV IV
Figure 1: Tear ferns (100×magnication). Type I (control): uniform and compact branched fern. Type II: the number of branches decreased,
while the interval increased. Type III: the number of branches decreased signicantly, and the interval space increased signicantly. Type IV:
the number of ferns is low, and the pattern is indenite.
4 Journal of Ophthalmology
Comparing the VKC group vs. healthy controls at
baseline, we found a significant increase in the degree of the
TFT that was 2.43 ± 0.80 SD in VKC subjects and 1.17 ±
0.40 SD in healthy subjects (p< 0.001) (Figure 2(a)). 'is
indicated a pathological alteration of the lacrimal mucous
layer. In addition, VKC patients had an increased number of
goblet cells, 30 ± 20 SD cells/field, compared to healthy
controls, 25 ± 11 SD cells/field, although this was not sta-
tistically significant (Figure 2(b)). 'e concentration of
MUC5AC did not show significant differences between
patients with VKC and healthy controls: VKC: 4,103.33 ±
286.35 SDpg/mL vs. healthy: 3,795.40 ± 837.44 SDpg/mL
(Figure 2(c)).
Probably, this indicates a pathological alteration of the
lacrimal mucous layer related to the production of fibro-
blastic material. An irritation of the goblet cells without
statistically significant variation of their number and of the
concentration of MUC5AC is present.
By correlating the clinical and biological parameters, the
TFTscore showed a direct correlation withmucous secretion
severity (p � 0.004, R � 0.373) and conjunctival
chemosis (p � 0.031, R � 0.278), indicating that in
patients with secretion and severe chemosis, TFT also
demonstrates poor quality of the lacrimal mucous compo-
nent (Figures 3(a) and 3(b)).
'e greatest number of conjunctival goblet cells corre-
lated significantly with the greater severity of the tarsal
papillae (p � 0.005, R � 0.499) and limbal nodules
(p � 0.047, R � 0.328). In addition, a statistically significant
inverse correlation between the number of goblet cells and
the duration of the chronic disease was demonstrated
(p � 0.048, R � −0.465) for probable chronic damage to the
conjunctival tissue (Figures 4(a)–4(c)).
'e lacrimal MUC5AC levels correlated inversely with
TSS (p � 0.042, R � −0.356) (Figure 5(a)) and with TFTscore
(p � 0.047, R � −0.427) (Figure 5(b)) of VKC patients.'ese
data indicated that a higher concentration of MUC5AC
correlated with a less severe VKC and with a better quality of
the tear mucous component.
Patients were re-evaluated 3 months after the start of
1% CY topical therapy, and no side effect attributable
to the use of topical drug was found (Figures 6(a)–6(c) and
7(a)–7(c)) Some signs and symptoms of pathological ac-
tivity improved after CY if compared to baseline, such as
the following:
(1) Conjunctival hyperemia/chemosis, baseline 2.5
(±0.5 SD) score, and posttherapy 0.40 (±0.49 SD)
score (p � 0.001)
(2) Tarsal papillae, baseline 2.3 (±0.5 SD) score, and
posttherapy 1.61(±0.2 SD) score (p � 0.016)
(3) Lacrimation, baseline 2.3 (±0.7 SD) score, and
posttherapy 0.65 (±0.06 SD) score (p � 0.045)
(4) TFT, baseline 2.43 (±0.80 SD) score, and posttherapy
1.93 (±0.67) score (p � 0.044)
(5) Improved density of conjunctival goblet cells,
baseline 30 (±20 SD) cells/field, and posttherapy 23
(±8 SD) cells/field (p � 0.044)
'ere were no changes in lacrimal MUC5AC levels,
baseline 4,103.33 (±286.35 SD) pg/mL, and posttherapy
3,909.18 (±606.01 SD) pg/mL.
4. Discussion
In our study, we evaluated the clinical and structural
modifications of the lacrimal mucinic component in patients
affected by VKC. In particular, the results obtained dem-
onstrated for the first time that there was a significant al-
teration of the lacrimal mucus in subjects with VKC
compared to controls, andmoreover, the degree of alteration
of the lacrimal mucin component correlated significantly
with the severity of the pathology. In addition, the pa-
rameters of the disease showed a significant improvement
after immunomodulatory therapy with topical CY.
Tabbara and Okumoto were the first to report the use
of ferning as a qualitative test for ocular tear discomfort in
91% of patients with several forms of conjunctivitis [16].
Beside, Norn (1994) believes, after having examined for
various ocular disorders 225 subjects, that the ferning
method has a sensitivity and a specificity of the same order
as the commonly used tests for qualitative and quanti-
tative lacrimal film (Schirmer I, BUT, rose bengale, lac-
toferrin) [15]. Other authors suggest that TFT could be
used as a simple, inexpensive, and low-invasive test to
clinically evaluate the tear film [13]. Both the BUT and
TFT tests reflect the dysfunction of tear mucin indirectly
[17]. Our research shows that TFT could be useful in the
objective evaluation of tear film and also be a marker of
Table 1: Clinical and demographic characteristics of 47 VKC
patients.
Age range 3–16 years
Age (average ± SD) 8.8 ± 4.7 years
VKC onset (average ± SD) 2.7 ± 1.3 years
Sex: male and female 38 (79.85%) 9 (20.15%)
Forms of VKC
Tarsal: 30 (63.83%)
Limbal: 12 (25.53%)
Mixed: 3 (6.38%)
Corneal: 2 (4.26%)
Total score of signs 12.5 ± 2.0 SD
Total score of symptoms 8.1 ± 2.1 SD
TFT score (average ± SD) 2.43 ± 0.80
Lacrimal MUC5AC (pg/ml) 4,103.33 ± 286.35 SD
Density goblet (cells/field) 30.0 ± 20.0 SD
Score of signs (TSS) Average ± SD
Hyperemia/chemosis conjunctival 2.5 ± 0.5
Mucous and serious secretions 2.3 ± 0.7
Tarsal papillae < 3mm 2.3 ± 0.5
Tarsal papillae > 3mm 2.2 ± 0.4
Horner–Trantas nodules 2.5 ± 0.2
Epithelial keratitis 0.5 ± 0.02
Score of symptoms (TSyS) Average ± SD
Itching and photophobia 4.0 ± 0.7
Tearing 2.1 ± 0.8
Foreign body sensation 2.0 ± 0.6
VKC: vernal keratoconjunctivitis; SD: standard deviation; TFT: tear ferning
test.
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Figure 2: Signicant increase of the TFT (tear ferning test) score in VKC (vernal keratoconjunctivitis) patients, 2.43 ± 0.80 SD, vs. controls,
1.17 ± 0.40 SD (p< 0.001) (a). Increase in the goblet cells density, though not statistically signicant, 30 ± 20 SD cells/eld in VKC patients,
vs. controls, 25 ± 11 SD cells/eld (b). e concentration of MUC5AC does not show signicant dierences between VKC patients, 4,103.33± 286.35 SD pg/mL, and controls, 3,795.40 ± 837.44 SD pg/mL (c).
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Figure 3: e tear ferning test (TFT) score shows direct correlation with mucous secretion severity (p  0.004, R  0.373) (a) and
conjunctival chemosis (p  0.031, R  0.278) (b), indicating altered quality of the lacrimal mucous component.
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therapeutic efficacy in patients with VKC. Indeed, there
are some factors that may change TFT, and the exact
nature of what determines the pattern is still not fully
understood [13]. In fact, rapid crystallisation of the tears,
evaporation, temperature, humidity, impurities, role of
electrolytes, spatial location of organic molecules, etc. play
a role in the formation of the ferns under the microscope
[13]. Precisely for these reasons, according to other au-
thors, it could be more useful to use other tests like
counting the number of goblet cells, or rose bengal 1%
stain, or lissamine green 2% stain score [18, 19]. For now,
the recent literature (Zeev, 2014) asserts that the nu-
merous diagnostic tests used are not yet widely accepted
and are often not reproducible [20].
Data of our research were accompanied by the dem-
onstration of an increased density of goblet cells in the
conjunctival epithelium of VKC patients with a more severe
score of tarsal and limbal papillae, both of which are indexes
of disease severity [21]. Aragona et al. demonstrated that, in
the conjunctival epithelium of VKC patients, there were
alterations in calcium density, intercellular junctions, the
amount of nuclear chromatin, and the degree of cellular
keratinization with a higher number of goblet cells, but
smaller in shape than in healthy controls [22]. In addition,
we observed under optical microscope that the goblet cells
appeared to be clustered and sometimes clotted in mucine
clusters associated with the presence of metaplasic cellular
specimens with some pyknotic nuclei [22] (Figure 8).
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Figure 4: 'e greatest number of conjunctival goblet cells correlates significantly with the greater severity of the tarsal papillae (p � 0.005, R � 0.499)
(a), and limbal nodules (p � 0.047, R � 0.328) (b). In addition, inverse correlation between the number of goblet cells and the duration of the chronic
disease was demonstrated (p � 0.048, R � −0.465) for probable chronic damage to the conjunctival tissue (c).
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Figure 5: Lacrimal MUC5AC levels correlates inversely with TSS (total score of the signs) (p � 0.042, R � −0.356) (a) and with TFT (tear
ferning test) score (p � 0.047, R � −0.427) (b) of VKC (vernal keratoconjunctivitis) patients for less severe VKC and better quality of the tear
mucous component.
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Conjunctival epithelium, therefore, reacts to the in-
flammatory stimulus with structural changes that can be
considered partly as defense mechanisms and partly as
degenerative signs. On the contrary, in both type-1, IgE-
mediated, and type-4 hypersensitivity reactions, T-lym-
phocytes play a role in the development of VKC disease.
Subsequently, the increase in mucus secretion could also
play an important role in the pathogenesis of the disease by
providing a network on which allergens may bind, stressing
inflammatory stimulation.'is could indicate a pathological
alteration of the lacrimal mucous layer related to infiltration
of conjunctival, limbal, and corneal inflammatory cells with
production of fibroblastic material. In fact, the conjunctiva is
characterised by an infiltration of inflammatory cells, es-
pecially eosinophils, mast cells, and T-lymphocytes
[3, 21–23]. Patients with VKC have been shown to have
increased levels of activated CD4+, '2-lymphocites, and of
inflammatory cytokines IL-3, IL-4, IL-5, and IL-6, indicating
that there is a hypersensitivity reaction to an unknown
pathogen [3, 21–23]. Inflammatory cytokines may regulate
the secretion, proliferation, and apoptosis of goblet cells
[24–26], while allergic mediators such as histamine, leu-
kotrienes, and prostaglandins directly stimulate the secre-
tory activity of these cells [24–27].
Our patients showed only an irritation of the goblet cells
without a statistically significant variation of their number
and of MUC5AC concentration. 'is aspect would represent
the first phase of conjunctival inflammatory response. With
the persistence of the inflammatory stimulus, the degenerative
cell phenomena would manifest themselves as the sign of
persistent damage to the ocular surface [22].
Moreover, we showed that, in patients with long-term
disease, the density of conjuntival goblet cells is lower
(Figure 4(c)), indicating a progressive squamous metaplasia
of the conjunctiva associated with the duration of chronic
inflammation. 'is could be due to the fact that in-
flammatory mediators initially stimulate a hyperplasia of
conjunctival goblet cells while the persistence of the in-
flammation could cause a reduction in the density of goblet
cells [21–23]. In our study, we also evaluated the tendency of
the number of conjunctival goblet cells to normalise in
patients with VKC after topical CY therapy. Although these
data do not reach statistical significance, they stimulate
a reflection on the immunoregulatory properties of drug
treatment. 'erapeutic activity could be useful to stimulate
the still viable cells that in just 3 months of topical therapy
have recovered their functionality [28, 29].
As is well known, CY is an immunomodulator that
reduces the proliferation of CD4+ lymphocytes through
interleukin-2 (IL-2) transcription blockade; it reduces
conjunctival fibroblasts and IL-1 production [2, 30, 31]. CY
also has an inhibitory effect on the activation of eosinophils,
basophils, andmast cells and on the release of histamine, and
inflammation mediators [30, 32]. We noticed a significant
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Figure 6: Some signs of pathology improvement 3 months after the start of CY (cyclosporine) therapy, such as: conjunctival hyper-
emia/chemosis, baseline 2.5 (±0.5 SD) score, and posttherapy 0.40 (±0.49 SD) score (p � 0.001) (a); tarsal papillae, baseline 2.3 (±0.5 SD)
score, and posttherapy 1.61 (±0.2) score (p � 0.016) (b); and lacrimation, baseline 2.3 (±0.7 SD) score, and posttherapy 0.65 (±0.06 SD) score
(p � 0.045) (c).
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improvement in the signs and symptoms of patients with
VKC after 3 months of 1% CY topical therapy [32, 33]. Our
data did not reveal dierences in the concentration of lac-
rimal MUC5AC between patients with VKC and healthy
controls, but correlations with clinical data showed a greater
concentration ofMUC5AC in the tears of less severe patients
and with a better quality of mucus (Figures 5(a) and 5(b)).
Such evidence suggests a protective role of MUC5AC, where
a higher concentration of lacrimal MUC5AC is associated
with better quality of the tear mucus component. In fact, we
know that MUC5AC contributes to making the tear lm
a non-Newtonian viscoelastic structure, capable of modi-
fying its viscosity depending on the size of the applied force,
thereby reducing the friction between the eye and eyelid
[24, 27].
5. Conclusions
is research conrmed the data of the literature on e£cacy
of topical CY therapy in patients with VKC, demonstrating
a statistically signicant improvement in clinical and
structural ocular in¤ammation. e results also showed, for
Figure 8: Observation of conjunctival cytogenes by an optical microscope. e goblet cells appear to be clustered and clotted in mucine
clusters associated with the presence of metaplasic cellular specimens with some pyknotic nuclei.
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Figure 7: Some signs of pathology improvement 3 months after the start of CY (cyclosporine) therapy, such as TFT (tear ferning test),
baseline 2.43 (±0.80 SD) score, and posttherapy 1.93 (±0.67) score (p 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pg/ml) and after therapy (3,909.18 ± 606.01 SD pg/ml) (c), even because a 3-month treatment period is too short to evaluate the possible
functional improvement of the conjunctiva in patients with chronic VKC (vernal keratoconjunctivitis).
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the first time, a significant alteration of the lacrimal mucinic
component evaluated by TFT in subjects with VKC com-
pared with healthy controls, before and after CY topical
therapy.'ese observations encourage to consider a possible
use of TFT in daily clinical practice, and the density of
conjunctival goblet cells in VKC patients could be a marker
of duration of the disease.
A larger study population and an increase in observation
time by at least 12 months after therapy will be necessary to
better understand the role of mucins in maintaining the
integrity of the mucus barrier and of the ocular surface. All
this, in order to lead to a therapeutic strategy to reduce the
signs and symptoms, avoid conjunctival fibrosis, and allow,
when possible, healing from the disease.
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